News and notifications

Suspicion of rare eye condition from Ozempic use to be investigated further

16 December 2024

The Danish Medicines Agency will request the European Pharmacovigilance Risk Assessment Commit-tee, PRAC, to assess two new Danish register-based studies from the University of Southern Denmark. The studies point to a potential increased risk of a rare eye condition, NAION, in patients receiving the diabetes medicine Ozempic.

EU one step closer to electronic product information

16 January 2025

Common nordic packages for better availability

02 December 2024

Nils Falk Bjerregaard new Director General of the Danish Medicines Agency

03 October 2024